# Frexalimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/frexalimab

> The next catalyst for frexalimab, sponsored by Sanofi (SNY), is its topline data readout, Apr to Jul 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | frexalimab |
| Codes | SAR441344 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Type 1 Diabetes Mellitus](https://sec-api.dev/indications/type-1-diabetes-mellitus), [Multiple Sclerosis](https://sec-api.dev/indications/multiple-sclerosis), [Kidney Transplant Rejection](https://sec-api.dev/indications/kidney-transplant-rejection) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Type 1 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06111586 (Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06111586

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Type 1 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06111586 (Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06111586

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07325292 (Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07325292

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07325292 (Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07325292

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06141486 (Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06141486

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06141486 (Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06141486

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Kidney Transplant Rejection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07412470 (A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-15 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07412470

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Kidney Transplant Rejection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07412470 (A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-15 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07412470

## Same indication

- [BMF-219](https://sec-api.dev/pdufa/bmf-219) (BMEA)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Imu-838 tablets](https://sec-api.dev/pdufa/imu-838) (IMUX)
- [LY3541860](https://sec-api.dev/pdufa/ly3541860) (LLY)
- [MRNA-1195](https://sec-api.dev/pdufa/mrna-1195) (MRNA)
- [Kesimpta (ofatumumab)](https://sec-api.dev/pdufa/ofatumumab) (NVS)
- [Zeposia (ozanimod hydrochloride)](https://sec-api.dev/pdufa/ozanimod) (BMY)
- [Technosphere insulin](https://sec-api.dev/pdufa/technosphere-insulin) (MNKD)
- [Tegoprubart](https://sec-api.dev/pdufa/tegoprubart) (ELDN)
- [TZIELD® (teplizumab)](https://sec-api.dev/pdufa/teplizumab) (SNY)
- [Aubagio (teriflunomide)](https://sec-api.dev/pdufa/teriflunomide) (SNY)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04), [July 2027](https://sec-api.dev/fda-calendar/2027-07), [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/frexalimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Frexalimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/frexalimab

```bibtex
@misc{secapidev_pdufa_frexalimab_20261116,
  title        = {Frexalimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/frexalimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_frexalimab_20261116","title":"Frexalimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/frexalimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
